ImClone Systems’ anti-insulin-like growth factor-1 receptor (IGR-IR) monoclonal antibody (known as IMC-A12) has received 10 proposals for Phase I/II trials from the Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI). The proposed trials follow NCI’s request for specific disease-directed studies among NCI investigators at academic institutions, clinical trial consortia and NCI-sponsored oncology c...